Biogen is calling it quits on a late-stage Parkinson’s trial as part of an ongoing R&D reorganization.
The Cambridge, MA-based biotech
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
